Status:
COMPLETED
Safety and Efficacy of Combining Intranasal Insulin & Acute Exercise
Lead Sponsor:
Michigan State University
Conditions:
Insulin
Exercise
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To determine if physical activity engagement alters the dose-response profile and safety of administration of insulin into the intranasal mucosa.
Detailed Description
Using a randomized placebo controlled double-blind pre-posttest design, participants will be randomly assigned to receive a dose of either 0, 20, 40, 60, 80, 100, or 120 IU of NovoLog insulin aspart p...
Eligibility Criteria
Inclusion
- Participants must be over the age of 18..
- Participants must have normal or corrected-to-normal vision in order to complete the cognitive task.
Exclusion
- Lack of consent.
- Presence of any major neurological health issues, brain trauma, or concussion with loss of consciousness assessed through a health history and demographics questionnaire.
- Type I or Type II Diabetes
- Self-reported pregnancy
- Currently has any type of inflammation or blockage of the nasal passageways (i.e. allergies or a cold affecting the sinuses).
Key Trial Info
Start Date :
June 15 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 20 2020
Estimated Enrollment :
116 Patients enrolled
Trial Details
Trial ID
NCT04292535
Start Date
June 15 2018
End Date
February 20 2020
Last Update
June 21 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Kinesiology
East Lansing, Michigan, United States, 48824